Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. China Meheco Group Co's Revenue for the
three
months ended in Mar. 2026 was ¥8,189 Mil. China Meheco Group Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was ¥14,922 Mil.
Hence, China Meheco Group Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.55.
China Meheco Group Co (SHSE:600056) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
China Meheco Group Co Receivables Turnover Related Terms
China Meheco Group Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for China Meheco Group Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600056 vs MCK, COR, CAH: Receivables Turnover Comparison
For the Medical Distribution subindustry, China Meheco Group Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Meheco Group Co Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Meheco Group Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where China Meheco Group Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Meheco Group Co (SHSE:600056) has a Receivables Turnover of 0.55 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on China Meheco Group Co and its competitors. According to the industry distribution chart, China Meheco Group Co ranks #101 out of 119 companies in the Medical Distribution industry, placing it in the top 84.9%.
Is China Meheco Group Co's Receivables Turnover too high?
China Meheco Group Co's current Receivables Turnover is 0.55. The Medical Distribution industry median Receivables Turnover is 4.55. China Meheco Group Co's value of 0.55 is 87.9% below this industry median. Based on the distribution chart, China Meheco Group Co ranks #101 out of 119 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, China Meheco Group Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Meheco Group Co's Receivables Turnover compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Meheco Group Co ranks #101 out of 119 companies for Receivables Turnover. This places China Meheco Group Co in the lower half of its industry. The industry median Receivables Turnover is 4.55. China Meheco Group Co's value of 0.55 is 87.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.55, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Meheco Group Co's current Receivables Turnover of 0.55 is 87.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on China Meheco Group Co and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Meheco Group Co's current Receivables Turnover is 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Meheco Group Co stock overvalued right now?
Based on GuruFocus' analysis, China Meheco Group Co (SHSE:600056) is currently considered Fairly Valued. The stock's GF Value™ is ¥10.47, compared to a current price of ¥9.53 — trading 9% below its estimated fair value. The current Receivables Turnover is 0.55 and 87.9% below the Medical Distribution industry median of 4.55. China Meheco Group Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For China Meheco Group Co (SHSE:600056), the current Receivables Turnover is 0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Meheco Group Co (SHSE:600056) Overvalued in 2026?
Based on GuruFocus' analysis, China Meheco Group Co stock appears to be undervalued.
The current stock price of ¥9.53 is trading 9% below its estimated GF Value™ of ¥10.47.
GuruFocus considers China Meheco Group Co to be Fairly Valued.
Key valuation signals for SHSE:600056:
Receivables Turnover: 0.55
GF Value™: ¥10.47 vs. price of ¥9.53 (9% below fair value)
Industry Position: 87.9% below the Medical Distribution median (#101 of 119)
No single metric tells the full story. See the SHSE:600056 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Meheco Group Co Ltd is engaged in the distribution and trading of botanical medicines, medical instruments, and pharmaceuticals. It offers botanic medicines and herbal products, as well as exports of natural medicines, including herbs, spices, plant extracts, bee products, and Chinese traditional medicines. The company's business scope covers the whole industry chain, from research and development, cultivation and processing, manufacturing, distribution, and logistics to international trading, academic promotion, and technical service. The corporation provides trading services for customers in the pharmaceutical and chemical field, covering APIs, preparations, biologicals, blood products, and others.
65GF Score
Get the complete analysis for SHSE:600056
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600056 has been successfully added to your 
